Xeris Biopharma Holdings, Inc. (XERS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98422E1038
Xeris Biopharma Holdings, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 291.85 m USD |
| Gross profit | 249.28 m USD |
| Operating income | 24.90 m USD |
| EBIT | 29.64 m USD |
| Net income | 554,000.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
More stocks
- Shenzhen Sed Industry Co Ltd (000032.SZ)
- Xiamen Voke Mold & Plastic Engineering Co. Ltd. (301196.SZ)
- Lily Group Co Ltd (603823.SS)
- SF Diamond (300179.SZ)
- C Sun Manufacturing Ltd (2467.TW)
- Jangho Group Co Ltd (601886.SS)
- RLX Technology Inc (RLX)
- Eastern Communications Co Ltd A (600776.SS)
- BLACKLINE, INC. (BL)
- BioMar Group A/S (BIOMAR.CO)
- Beijing Jetsen Tech Co (300182.SZ)
- HBX Group International PLC (HBX.MC)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.